Dow Jones
39.164,06 +36,26 (+0,09%) Nasdaq
17.858,68 +53,53 (+0,30%) Nikkei 225
39.543,99 +202,45 (+0,51%) EUR/USD
1,0696 -0,0013 (-0,12%) Bitcoin EUR
57.546,31 +827,32 (+1,46%) CMC Crypto 200
1.282,39 -1,44 (-0,11%)
Inhibikase Therapeutics, Inc. (IKT)
| Chiusura precedente | 1,3700 |
| Aperto | 1,4000 |
| Denaro | 0,0000 x 0 |
| Domanda | 0,0000 x 0 |
| Min-Max giorno | 1,3700 - 1,5000 |
| Intervallo di 52 settimane | 0,7900 - 3,8200 |
| Volume | |
| Media Volume | 51.033 |
| Capitalizzazione | 9,886M |
| Beta (mensile su 5 anni) | 1,41 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,3200 |
| Prossima data utili | 12 ago 2024 - 16 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 15,50 |
GlobeNewswireInhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment
BOSTON and ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today highlighted an analysis of eleven unblinded participants from the 201 Trial evaluating risvodetinib (IkT-148009) in untreated Parkinson’s disease. T
- GlobeNewswire
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy
BOSTON and ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that risvodetinib (IkT-148009) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment o
- GlobeNewswire
Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity
BOSTON and ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders in response to recent price volatility. Dear Fellow Shareholders of Inhibikase Therapeutics: We have watched, as ha
